Search results
Author(s):
Shino Kany
Added:
1 year ago
AHA 22 - Dr Shino Kany (Broad Institute of MIT and Harvard, Cambridge, MA, US) joins us to discuss the association of genetic risk and outcomes in patients receiving early rhythm control therapy for atrial fibrillation in the EAST-AFNET 4 trial.
EAST-AFNET 4 aimed to compare early rhythm control to usual care amongst patients with a recent diagnosis of atrial fibrillation, randomised in a 1:1…
View more
ESC 23: The SurHyb Trial
Author(s):
Alan Bulava
Added:
7 months ago
Video
Author(s):
Jonathan Piccini
Added:
1 year ago
AHA 22 - Dr Jonathan Piccini(Duke University Medical Center, Durham, US) joins us to discuss the findings of the NOVA Phase II trial (NCT03779841).
NOVA Phase II is a multicenter, randomized, dose-ranging study that aims to find the efficacy and safety of botulinum toxin type A (AGN-151607) (AbbVie)in preventing post-operative atrial fibrillation (POAF) in patients undergoing open-chest cardiac…
View more
Author(s):
Paul Wang
Added:
1 year ago
AHA 22: Dr Paul Wang (Cardiac Arrhythmia Service at Palo Alto, Stanford, CA, US) joins us remotely to discuss the findings of the ENHANCE-AF trial, originally presented at the American Heart Association's 2022 Scientific Sessions.
ENHANCE AF aimed to evaluate whether a shared-decision-making pathway tool would reduce the risk of stroke as a result of atrial fibrillation when compared to standard…
View more
Author(s):
Aiko Takami
,
Junichiro Miake
,
Masaru Kato
,
et al
Added:
1 year ago
Author(s):
Diana Hui Ping Foo
,
Alan Yean Yip Fong
,
Wael Almahmeed
Added:
1 year ago
Author(s):
Andreas Goette
Added:
2 years ago
In this short video interview, Prof Andreas Goette (St Vincenz Hospital Paderborn, Paderborn, DE) discusses the findings from the the EAST-AFNET 4 Trial. The trial investigated whether rhythm control therapy delivered within one year after AF diagnosis improves outcomes. The trial, presented at AHA 21, demonstrated that clinical benefit of early rhythm control was consistent in AF patterns.
…
View more
Author(s):
Mads Brix Kronborg
Added:
7 months ago
ESC 2023 — Dr Mads Brix Kronborg (Aarhus University Hospital, DE) joins us to discuss the findings from the DANPACE II Trial (NCT00236158).
DANPACE II (The DANPACE Investigator Group) trial aimed to compare patients who were randomised in a 1:1 ratio to either a base rate of 60 beats per minute and rate-adaptive DDD (DDDR-60 Group) or a base rate of 40bpm and non-rate adaptive DDD (DDD-40…
View more
Author(s):
Paulus Kirchhof
Added:
7 months ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577).
NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,…
View more
Ulrich Schotten
Job title: Full professor and Chairman of the Department of Physiology
Author